CME Presentations

Alzheimer's Disease


Presentations


Speakers

  • Stephen P. Salloway, MD, MS

    Stephen P. Salloway, MD, MS

    Stephen P. Salloway, MD, MS

    Professor of Neurology and Psychiatry

    Stephen Salloway, MD, MS, is chief of neurology and director of the Memory and Aging Program at Butler Hospital, and professor of neurology and psychiatry at the Alpert Medical School of Brown University in Providence, Rhode Island. Under his direction, the Butler Hospital Memory and Aging Program has conducted more than 75 clinical trials developing new diagnostic tests and treatments for memory loss, and his program is currently conducting 5 prevention trials for individuals at high risk for Alzheimer’s disease (AD). Dr Salloway has published over 300 scientific articles and abstracts, edited 3 books, and lectures widely about early diagnosis and treatment of AD. He received his MD from Stanford Medical School, and completed residencies in neurology and psychiatry at Yale University.
  • Marwan Sabbagh, MD, FAAN, CCRI

    Marwan Sabbagh, MD, FAAN, CCRI

    Marwan Sabbagh, MD, FAAN, CCRI

    Director Lou Ruvo Center for Brain Health

    Marwan Noel Sabbagh, MD, FAAN, is director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, Nevada. Considered one of the leading experts in Alzheimer’s disease (AD) and dementia, he dedicated his career to finding a cure for AD and other age-related neurodegenerative diseases. As the leading investigator of many prominent AD prevention and treatment trials, Dr Sabbagh has authored or co-authored over 350 medical and scientific articles on AD research, and is the author of The Alzheimer’s Answer: Reduce Your Risk and Keep Your Brain Healthy. He is the Camille and Larry Ruvo endowed chair for Brain Health and editor in chief of Neurology and Therapy. He has been recognized with numerous awards, including the 2015 WestMarc Innovator Award.

CME Information

Early Diagnosis and Management of Alzheimer’s Disease: Is Now the Time for Disease-Modifying Agents?


Einstein LogoMontefiore Logo PQH Logo

LEARNING OBJECTIVES

At the conclusion of this activity, participants will be able to:

  • Incorporate proactive evaluation of all cognitive domains and biomarkers, as needed, to achieve an accurate and early diagnosis of MCI and early AD
  • Apply expert recommendations for the optimal early detection of AD
  • Summarize the therapeutic implications of current data on disease-modifying immunotherapies and other agents in late-stage clinical development aimed at slowing disability progression
Presented by the Albert Einstein College of Medicine and Montefiore Medical Center in Joint Providership with PlatformQ Health Education, LLC

ACKNOWLEDGEMENT

This activity is supported by an educational grant from Biogen.

TUITION

Complimentary

ACCREDITATION STATEMENT

The activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and PlatformQ Health Education, LLC. Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION STATEMENTS

Live Internet Activity

Albert Einstein College of Medicine designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Enduring Material

Albert Einstein College of Medicine designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

OTHER CREDITS

The American Academy of Nurse Practitioners (AANP) and American Nurses Credentialing Center (ANCC) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.

DATE OF RELEASE/EXPIRATION

Live Internet Activity

Monday, July 20, 2020 from 12:30 – 1:30 PM ET

Enduring Material

The enduring material will be available from July 20, 2020 to July 20, 2021.

INTENDED AUDIENCE

The intended audience for this activity is neurologists, primary care physicians (including those specializing in family medicine and internal medicine), psychiatrists, geriatricians and physicians in long-term care settings, advance practice clinicians, and health care providers involved in the care of patients with dementia due to AD.

ESTIMATED TIME TO COMPLETE

This activity consists of one session, which should take approximately 1 hour to complete.

METHOD OF PARTICIPATION

There are no fees to participate in this activity. To receive credit, participants must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the posttest and activity evaluation. It is estimated that this module will take approximately 1 hour to complete. To receive AMA PRA Category 1 Credit™, participants must receive a minimum score of 70% on the posttest.

HARDWARE/SOFTWARE REQUIREMENTS

Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.

FACULTY DISCLOSURE

The "Conflict of Interest Disclosure Policy" of Albert Einstein College of Medicine requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience any relationship(s) with a pharmaceutical or equipment company. Any presenter whose disclosed relationships prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

The Albert Einstein College of Medicine also requires that faculty participating in any CME activity and anyone in a position to influence content disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States. -
Presenter Disclosures
Stephen Salloway, MD, MS Consulting Fee: Amgen, Biogen, Roche, Avid, Gemvax
Marwan N. Sabbagh, MD, FAAN, CCRI Consulting Fee: Allergen, Biogen, Grifols, Cortexyme, Roche-Genentech
Providers Disclosures
Einstein-Montefiore Center for Continuing Medical Education The Center for Continuing Medical Education (CCME) staff at Albert Einstein College of Medicine has no disclosures to report relevant to this activity.
PlatformQ Health Education, LLC Disclosures
Carol Drexel, Medical Director Has nothing to disclose relevant to this activity.
Bridget Griffin, Program Manager Has nothing to disclose relevant to this activity.


CONTACT INFORMATION

Please send all inquiries to: Montefiore Medical Center, CCME, 3301 Bainbridge Avenue, Bronx, New York 10467, or via phone at (718) 920-6674, or via fax to (718) 798-2336, or via email to cme@montefiore.org.

For issues with your CME Certificate, please contact NeuroSeriesLive or PsychiatryCareLive at 877-394-1306 or at Support@NeuroSeriesLive.com or Support@PsychiatryCareLive.com.

DISCLAIMERS (if applicable):

The material is prepared based on a review of multiple sources of information but is not exhaustive of the subject matter. Therefore, health care professionals and other individuals should review and consider other publications and materials about the subject matter other than relying solely on the information contained in this material.

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by Albert Einstein College of Medicine, NeuroSeriesLive, PsychiatryCareLive and PlatformQ Health Education, LLC or the program grantor. Reasonable efforts have been made to present educational subject matter in a balanced, unbiased fashion and in compliance with regulatory requirements. Each participant must use his/her personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.